Related Experiment Videos
High-dose methotrexate with folinic acid rescue.
American Journal of Hospital Pharmacy
|September 1, 1977
Summary
High-dose methotrexate with folinic acid rescue improves treatment effectiveness but requires careful monitoring. Understanding drug and patient factors is crucial for preventing methotrexate toxicity during this therapy.
Area of Science:
- Pharmacology
- Oncology
- Clinical Pharmacy
Background:
- Methotrexate is a critical chemotherapeutic agent.
- High-dose methotrexate (HD-MTX) requires careful administration to maximize efficacy and minimize toxicity.
- Folinic acid rescue is essential for preventing severe adverse events associated with HD-MTX.
Purpose of the Study:
- To review the pharmacology of methotrexate.
- To discuss the rationale and necessity of folinic acid rescue with HD-MTX.
- To identify factors influencing HD-MTX toxicity for improved patient monitoring by pharmacists.
Main Methods:
- Review of existing literature on methotrexate pharmacology.
- Discussion of clinical factors related to HD-MTX administration and toxicity.
- Analysis of drug- and patient-related variables impacting treatment outcomes.
Main Results:
- HD-MTX combined with folinic acid rescue enhances the therapeutic index of methotrexate.
- Specific critical factors and unusual toxicities associated with HD-MTX therapy are identified.
- Several variables affecting toxicity in this dual drug administration are highlighted.
Conclusions:
- High-dose methotrexate with folinic acid rescue offers improved therapeutic benefits.
- Pharmacists play a key role in monitoring patients due to potential drug- and patient-related toxicities.
- Further research is needed to determine optimal dosage and duration for this combined therapy.